Ondansetron Eugia (Uk) (Ondansetron)

Ondansetron acts on the serotonin pathway to prevent nausea and vomiting in several clinical contexts.

• Chemotherapy‑induced nausea and vomiting: prevents and controls nausea and vomiting caused by cytotoxic drugs.
• Radiotherapy‑induced nausea and vomiting: reduces nausea and vomiting triggered by radiation treatment.
• Postoperative nausea and vomiting: helps avoid nausea and vomiting after surgical procedures.

• Ondansetron selectively blocks serotonin 5‑HT3 receptors located in the chemoreceptor trigger zone of the central nervous system and on vagal afferents in the gastrointestinal tract. By inhibiting these receptors, it prevents the initiation of the vomiting reflex that is stimulated by chemotherapeutic agents, radiation, or surgical stress, thereby reducing nausea and emesis.

Common side effects are generally mild and transient.

Common Side Effects

• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Fatigue: feeling unusually tired or weak.
• Diarrhoea: loose, watery stools.
• Injection site pain: discomfort at the site of intramuscular or intravenous administration.

Serious or Rare Side Effects

• QT interval prolongation: potential cardiac rhythm disturbance.
• Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty.
• Serotonin syndrome: agitation, hyperthermia, muscle rigidity when combined with other serotonergic agents.
• Cardiac arrhythmia: irregular heartbeats beyond QT changes.
• Severe hypotension: marked drop in blood pressure.

Before using Ondansetron, consider the following safety measures.

• Cardiac assessment: evaluate patient history of arrhythmias or prolonged QT interval.
• Electrolyte monitoring: correct hypokalemia, hypomagnesemia, or hypocalcemia that may predispose to QT prolongation.
• Concomitant serotonergic drugs: use with caution when patients are on other serotonin‑modulating agents.
• Hepatic function: adjust use in patients with significant liver impairment.
• Pregnancy and lactation: assess risk‑benefit as safety data are limited.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Ondansetron may interact with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Apomorphine: co‑administration can cause severe hypotension and loss of consciousness.
• Other QT‑prolonging agents (e.g., quinidine, haloperidol): increase risk of cardiac arrhythmias.
• Serotonergic drugs (e.g., SSRIs, MAO inhibitors): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• Azole antifungals (ketoconazole, fluconazole): may increase ondansetron plasma levels.
• Macrolide antibiotics (erythromycin, clarithromycin): modestly raise drug exposure.
• Carbamazepine: may reduce ondansetron effectiveness.
• Dexamethasone: potential additive antiemetic effect, monitor for enhanced side effects.
• Opioids: monitor for additive constipation and sedation.